Table 4. Comparison of diagnostic thresholds for diabetes and treatment targets for blood glucose, systolic blood pressure (BP) and serum cholesterol across national guidelines in seven-country study of the management of diabetes and associated cardiovascular risk factors.
National guideline (country, issuing body, year of publication) | Diagnostic threshold, FPG (mg/dl) | Treatment target |
||
---|---|---|---|---|
Blood glucose (HbA1c or FPG) | Systolic BP (mmHg) | Serum lipids (mmol/l) | ||
Colombia, Ministry of Social Protection,28 2007 | ≥ 126 | < 7.0% HbA1c | < 140 | LDL < 2.6 |
England and Scotland, National Institute for Clinical Excellence,29 2008 | NA | < 6.5–7.5% HbA1c | < 140 | LDL < 3.0 |
TC < 5.0 | ||||
TG < 2.3 | ||||
Islamic Republic of Iran, Ministry of Health,30 2004 | ≥ 126 | < 140 mg/dl FPG | < 130 | LDL < 3.4 |
TC < 6.2 | ||||
TG < 2.3 | ||||
Mexico, Ministry of Health,31 1994 | ≥ 126 | < 140 mg/dl FPG | < 130 | TC < 6.2 |
TG < 2.3 | ||||
HDL > 0.9 | ||||
Thailand, National Health Security Office,32 2008 | ≥ 126 | < 6.5% HbA1c; 70–110 mg/dl FPG | < 130 | LDL < 2.6 |
TC 3.4–4.4 | ||||
TG < 1.7 | ||||
HDL ≥ 1.0 | ||||
United States, American Diabetes Association,33 2009 | ≥ 126 | < 7.0% HbA1c | < 130 | LDL < 2.6 |
TG < 1.7 | ||||
HDL > 1.0 | ||||
World, International Diabetes Federation,26 2005 | ≥ 126 | < 6.5% HbA1c; < 110 mg/dl FPG | < 130 | LDL < 2.5 |
TG < 2.3 | ||||
HDL > 1.0 |
FPG, fasting plasma glucose; HbA1c, glycosylated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; mg/dl, milligrams per decilitre; mmHg, millimetres of mercury; mmol/l, millimoles per litre; NA, not available; TC, total cholesterol; TG, triglycerides.